{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-108804","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.279977+00:00","generated_at":"2026-05-16T22:29:44.276125+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MeiraGTx licenses AAV-AIPL1 and gene therapy tools to Lilly for $75M upfront, up to $400M milestones","bullets":["Upfront payment of $75M; eligible for over $400M in total milestones, including up to $135M near-term.","Lilly gets exclusive worldwide rights to AAV-AIPL1 for LCA4, which restored vision in 11 blind children.","Also licenses proprietary intravitreal capsids, promoters (AI-generated), and riboswitch gene-editing rights.","MeiraGTx eligible for tiered royalties; retains ownership of certain technology improvements; Lilly funds all R&D and commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-108804","json":"https://secwatch.observer/filing/0001104659-25-108804.json","markdown":"https://secwatch.observer/filing/0001104659-25-108804.md","text":"https://secwatch.observer/filing/0001104659-25-108804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000110465925108804/0001104659-25-108804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000110465925108804/mgtx-20251107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:29:44.276125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}